ATRC
AtriCure, Inc. $55.14 +2.89% 2026-10-02 종가 기준핵심 지표
yfinance 기준분기 실적
매출·순이익 · yfinance연간 실적 5년
SEC 10-K · 회계연도 · 달러잉여현금흐름 $0.0B
잉여현금흐름 $0.0B
잉여현금흐름 $-0.0B
잉여현금흐름 $-0.0B
잉여현금흐름 $-0.0B
EPS 서프라이즈
최근 4분기 · 실제 vs 예상수익성·성장
최근 12개월 기준사업 개요
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tiss